Trial Profile
A PHASE 2, 16 WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED, PARALLEL GROUP PROOF-OF-CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF PAIN ASSOCIATED WITH CHRONIC ABACTERIAL PROSTATITIS
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Oct 2021
Price :
$35
*
At a glance
- Drugs Tanezumab (Primary)
- Indications Pelvic pain
- Focus Proof of concept; Therapeutic Use
- Sponsors Pfizer
- 19 May 2015 Pooled analysis (1035, 1010, 1019) results presented at the 110th Annual Meeting of the American Urological Association.
- 22 Sep 2012 Results published in Urology.
- 03 Apr 2012 Inclusion and exclusion criteria amended as reported by European Clinical Trials Database record.